OSCR
Oscar Health, Inc.
OSCR has the edge over TDOC overall, supported by stronger fundamentals.
TDOC
Teladoc Health, Inc.
TDOC's outlook is improving, though it still trails on the overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
TDOC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Healthy | |
| Healthy |
TDOC's cash flow and balance sheet are currently healthy, and its revenue is stable, but its profitability is under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
TDOC PE Valuation
TDOC has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over TDOC on the outlook, with more favorable revenue expectations.
TDOC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect TDOC's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over TDOC on earnings quality, reporting a profit while its opponent remains loss making.
TDOC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.86 | +$0.41 |
| Q2 2026 | -$0.99 | +$0.19 |
| Q1 2026 | -$0.97 | +$4.94 |
| Q4 2025 | -$1.14 | +$4.73 |
| Q3 2025 | -$1.27 | +$4.50 |
| Q2 2025 | -$1.18 | +$4.75 |
| Q1 2025 | -$5.91 | -$4.50 |
| Q4 2024 | -$5.87 | -$4.53 |
TDOC is still losing money, but far less than before: $0.86 per share over the past year, against $84.60 at its worst in late 2022.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over TDOC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over TDOC on profitability, with a higher operating margin.
TDOC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $605.1M | -3.4% |
| Q2 2026 | $606.9M | -4% |
| Q1 2026 | $613.8M | -2.5% |
| Q4 2025 | $642.3M | +0.3% |
| Q3 2025 | $626.4M | -2.2% |
| Q2 2025 | $631.9M | -1.6% |
| Q1 2025 | $629.4M | -2.6% |
| Q4 2024 | $640.5M | -3% |
TDOC's revenue grew through 2022 and has held roughly level since: $605M last quarter, down 3.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4.6% | +3.6 points |
| Q2 2026 | -6.1% | +2.5 points |
| Q1 2026 | -10% | +9.1 points |
| Q4 2025 | -5.6% | +1.9 points |
| Q3 2025 | -8.3% | -1.4 points |
| Q2 2025 | -8.6% | +122 points |
| Q1 2025 | -19% | -5.7 points |
| Q4 2024 | -7.5% | -2.2 points |
TDOC's operating margin was −4.6% last quarter, up 3.6 points from the same quarter a year ago, near the top of its range since 2019.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over TDOC on cash flow, with more consistent year-over-year improvement.
TDOC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $105.2M | +8.5% |
| Q2 2026 | $63.7M | -29% |
| Q1 2026 | $7.9M | -40% |
| Q4 2025 | $85.1M | +6.7% |
| Q3 2025 | $97M | -11% |
| Q2 2025 | $90.2M | +3.9% |
| Q1 2025 | $13.2M | +70% |
| Q4 2024 | $79.8M | -38% |
TDOC generated $262M in free cash flow over the past year, down 6.5% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
TDOC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +850K shares |
| 1 year | +2.8% | +4.9M shares |
| 3 years | +10% | +16.8M shares |
| 5 years | +14% | +22.4M shares |
| Available history | +151% | +109M shares |
TDOC has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
TDOC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.1x | Net Cash |
| Q2 2026 | -4.3x | Net Cash |
| Q1 2026 | -4.6x | Net Cash |
| Q4 2025 | -7.7x | Net Cash |
| Q3 2025 | -8.7x | Net Cash |
| Q2 2025 | -7.4x | Net Cash |
TDOC has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
TDOC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.1 | Neutral |
| Stochastic | 75.8 | Neutral |
TDOC's weekly RSI is 63 (neutral) and its Stochastic is 76 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TDOC PE vs Healthcare Sector
TDOC has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over TDOC on trend strength, trading above more of its moving averages.
TDOC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.92 | 26% above |
| 20 week MA | $7.22 | 20% above |
| 50 week MA | $6.68 | 30% above |
| 100 week MA | $7.51 | 16% above |
| 200 week MA | $12.6 | 31% below |
TDOC has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 31% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over TDOC on returns for 2026, with the stronger performance.
TDOC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $83.4 | $208.0 | +149% |
| 2021 | $208.0 | $95.1 | -54% |
| 2022 | $95.1 | $23.5 | -75% |
| 2023 | $23.5 | $21.6 | -8.4% |
| 2024 | $21.6 | $9.45 | -56% |
| 2025 | $9.45 | $7.12 | -25% |
| 2026 YTD | $7.12 | $8.69 | +22% |
TDOC has finished five years in a row lower, and it's up 22% so far in 2026.